Linezolididoneidad de prescripción y afectación de la función renal y hematológica

  1. Morales Molina, JA. 1
  2. Grau, S. 1
  3. Jiménez Martín, J. 1
  4. Mateu-De, Antonio J. 1
  5. Zarzuelo, A. 1
  6. Salas, E. 1
  1. 1 Universidad de Granada
    info

    Universidad de Granada

    Granada, España

    ROR https://ror.org/04njjy449

Journal:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Year of publication: 2006

Volume: 47

Issue: 4

Pages: 364-374

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Ars pharmaceutica

Abstract

The objective of the study was to evaluate the suitability of linezolid prescription, incidence of thrombocytopenia in critically ill patients and its infl uence on critical ill patients with renal disorder before the linezolid treatment. We observed that the 37.5% of linezolid prescriptions were in Non Approved Indications in Spain (NAIS). The incidence of thrombocytopenia was 5.9%. We observed a signifi cant improvement in renal function of patients after two weeks of linezolid treatment (p=0.024). The incidence of thrombocytopenia was similar to describe in bibliography. It seems to be necessary approved news indications in Spain.

Data source: Dialnet